Table 2.

Baseline characteristics of studies included in the Bayesian meta-analysis

Tumor stage	No. included cases			OS	DFS	RFS
	S	L	WR
cT1N0	76		76		0.95 (0.49, 1.86)
I	32	32		0.81 (0.46,1.43)
IA	31	93		1.50 (0.38,5.94)	1.34 (0.48, 3.73)
IA/IB	312	312		1.17 (0.89,1.52)		1.11 (0.87, 1.40)
cT1N0M0	68	104		0.89 (0.22,3.63)
	100	100		0.83 (0.21,3.33)		0.83 (0.24, 2.85)
I	39		60	1.21 (0.57, 2.59)		1.07 (0.54, 2.15)
T1a N0 M0	69	69		0.89 (0.22, 3.56)		1.10 (0.29, 4.25)
cT1a N0 M0	87	87		0.99 (0.57, 1.75)	1.14 (0.46–2.82)
	809	809		0.84 (0.69, 1.01)
I	38	71		2.16 (0.35, 13.3)		1.13 (0.26, 4.86)
IA2		235	29	0.31 (0.10, 0.93)
	90	124		1.22 (0.29, 5.15)	1.27 (0.59, 2.75)
	11503	821		1.28 (1.10, 1.49)
IA	378		1568	0.77 (0.66–0.91)
		209	209	0.59 (0.44, 0.78)
	209	209		1.45 (1.10, 1.91)